---
title: USJCMSP 2024 EID
---

- [Grants & Procurement](https://www.crdfglobal.org/grants-procurement/)
- [Contact Us](https://www.crdfglobal.org/contact-us/)

[Facebook](https://www.facebook.com/CRDFGlobal) <https://twitter.com/CRDFGlobal> [Instagram](https://www.instagram.com/crdfglobal/)[Linkedin](https://www.linkedin.com/company/crdf-global)

[![](https://insights.crdfglobal.org/hubfs/crdf-logo.svg)](https://crdfglobal.org/)

- WHO WE ARE
  
  #### [Our Story](https://crdfglobal.org/our-story/)
  
  #### [Mission, Vision & Values](https://crdfglobal.org/mission-vision-values/)
  
  #### [Leadership](https://crdfglobal.org/leadership)
  
  #### [Our Experts](https://crdfglobal.org/experts)
  
  #### [Clients & Partners](https://crdfglobal.org/partners)

  ![Who we are mega menu](https://www.crdfglobal.org/wp-content/uploads/2022/06/who-we-are-menu.jpg)
  
  More than 30 years advancing international security, technology, and economic progress in over 120 countries.
- WHAT WE DO
  
  #### [Chemical, Biological & Nuclear Security](https://www.crdfglobal.org/what-we-do/cbrne-security-counterproliferation/)
  
  #### [Cybersecurity & Digital Resilience](https://www.crdfglobal.org/what-we-do/cybersecurity/)
  
  #### [Research, Data & Emerging Technology Security](https://www.crdfglobal.org/what-we-do/research-data-and-technology-security/)

  #### [Security Cooperation & Exchanges](https://www.crdfglobal.org/what-we-do/international-exchanges/)
  
  #### [Border Security & Strategic Trade Controls](https://www.crdfglobal.org/what-we-do/strategic-trade-border-security/)
  
  #### [Health Security and Research](https://www.crdfglobal.org/what-we-do/global-health/)

  ![What we do mega menu](https://www.crdfglobal.org/wp-content/uploads/2022/07/MegaMenu_Website_Images_Ratios_SizesWhat-We-Do-Mega-Menu.png)
  
  Addressing evolving security and prosperity challenges through strategically tailored solutions.
- HOW WE DELIVER
  
  ### CORE CAPABILITIES
  
  #### [Travel & Logistics](https://crdfglobal.org/capabilities/travel-logistics/)
  
  #### [Specialized Equipment Procurement](https://crdfglobal.org/capabilities/specialized-equipment-procurement/)
  
  #### [Technical & Professional Trainings](https://crdfglobal.org/capabilities/technical-and-professional-trainings/)
  
  #### [Fellowships & Exchanges](https://crdfglobal.org/capabilities/fellowships-and-exchanges/)
  
  #### [Grants & Research Competitions](https://crdfglobal.org/capabilities/grants-research-competitions/)
  
  #### [Security Strengthening](https://crdfglobal.org/capabilities/security-strengthening/)

  ### INTEGRATED SOLUTIONS
  
  #### [Program Design and Management](https://crdfglobal.org/integrated-solutions/program-design-and-management/)
  
  #### [Quality Framework](https://crdfglobal.org/integrated-solutions/quality-framework/)
  
  #### [Monitoring, Evaluation and Learning](https://crdfglobal.org/integrated-solutions/monitoring-evaluation-and-learning/)
  
  #### [Remote Training & Learning](https://crdfglobal.org/integrated-solutions/remote-training-and-learning/)

  ![How we deliver mega menu](https://www.crdfglobal.org/wp-content/uploads/2022/01/how-we-deliver-menu-v2.jpg)
  
  Recognized leader in global program delivery, combining technical expertise with flexible, locally driven solutions.
- [WHERE WE WORK](https://crdfglobal.org/where-we-work/)
- [NEWS & INSIGHTS](https://www.crdfglobal.org/news/)
- [CAREERS](https://crdfglobal.org/careers/)

- [\> Home](https://insights.crdfglobal.org/usjcmspeid2024)
- [\> General Registration](https://insights.crdfglobal.org/usjcmspeid2024-1)
- [\> Speaker Registration](https://insights.crdfglobal.org/usjcmspeid2024-1-1)
- [\> Plenary Agenda](https://insights.crdfglobal.org/usjcmspeid2024-agenda)
- [\> Panel Agendas](https://insights.crdfglobal.org/usjcmspeid2024panels)
- [\> Travel Information](https://insights.crdfglobal.org/usjcmspeid2024-travel)
- [\> IDRIC Symposium](https://idric.kr/)
- [\> Abstract eBooks](https://insights.crdfglobal.org/usjcmspeid2024_ebooks)

---

![USJCMSP logo5 title](https://insights.crdfglobal.org/hs-fs/hubfs/USJCMSP%20logo5%20title.jpg?width=300&height=179&name=USJCMSP%20logo5%20title.jpg "USJCMSP logo5 title")

## The Joint 24th International Conference on Emerging Infectious Diseases in the Pacific Rim of the U.S.-Japan Cooperative Medical Sciences Program (USJCMSP) in collaboration with the 2nd International Symposium for Infectious Diseases Research Institutes Cooperation (IDRIC)

![logo1 (003)](https://insights.crdfglobal.org/hs-fs/hubfs/logo1%20(003).png?width=125&height=125&name=logo1%20(003).png "logo1 (003)")

![NIH\_Master\_Logo\_Vertical\_2Color-PNG (002)](https://insights.crdfglobal.org/hs-fs/hubfs/NIH_Master_Logo_Vertical_2Color-PNG%20(002).png?width=125&height=110&name=NIH_Master_Logo_Vertical_2Color-PNG%20(002).png "NIH_Master_Logo_Vertical_2Color-PNG (002)")

![KDCA\_KNIH\_KNIID LOGO change](https://insights.crdfglobal.org/hs-fs/hubfs/KDCA_KNIH_KNIID%20LOGO%20change.jpg?width=350&height=58&name=KDCA_KNIH_KNIID%20LOGO%20change.jpg "KDCA_KNIH_KNIID LOGO change")

![IVI\_logo (002)-1](https://insights.crdfglobal.org/hs-fs/hubfs/IVI_logo%20(002)-1.png?width=250&name=IVI_logo%20(002)-1.png "IVI_logo (002)-1")

Disclaimer: The views expressed in written conference materials or publications and by speakers and moderators at HHS-sponsored conferences do not necessarily reflect the official policies of the Department of Health and Human Services (HHS), nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

---

### Cancer Panel Agenda

###### Thursday| 7 March 2024 | DAY THREE

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

9:45-10:00 | Welcome and Introductory Comments | Marrie Ricciardone and Tohru Kiyono

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

SESSION ONE: EBV and Gastric Cancer and Lymphoid Malignancies

*Moderator: Haruhiko Sugimura and Atsushi Kaneda*

10:00-10:20 | EBV rewires 3D chromatin and epigenetically drives gastric tumorigenesis | **Atsushi Kaneda,** Chiba University, Chiba, Japan 

10:20-10:40 | Epstein-Barr Virus Disrupts Sphingolipid Metabolism to Maintain Viral Latency in Gastric Carcinoma | **Suk Kyeong Lee,** The Catholic University of Korea

10:40-11:00 | Epstein-Barr virus strains transmitted among Transeurasian language speakers | **Teru Kanda,** Tohoku Medical and Pharmaceutical University

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

11:00-11:20 | Coffee Break

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

11:20-11:40 | Advances in pathology and treatment of chronic active Epstein-Barr virus Disease | **Yu Uemura,** St. Marianna University School of Medicine

11:40-12:00 | Inhibitors of viral microRNA promote Epstein-Barr virus-associated cancer cell death | **Hisashi Iizasa,** Shimane University

12:00-12:20 | Proposed

12:20-12:40 | Discussion

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

12:40-14:00 | Lunch Break

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

SESSION TWO: HPV and Cancer 

*Moderators: Marie Ricciardone and Tohru Kiyono*

14:00-14:20 | Intra-Patient Variation of Human Papillomavirus Genome Contributing to Cervical Cancer Development | **Iwao Kukimoto,** National Institute of Infectious Diseases

14:20-14:40 |Carcinogenesis of HPV18-associated cervical cancer | **Ayumi Taguchi,** Osaka University, Immunology Frontier Research Center

14:40-15:00 | In vitro carcinogenesis model of HPV- induced cervical adenocarcinoma | **Tomomi Nakahara,** National Cancer Center Research Institute, Japan

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

15:00-15:20 | Break 

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

15:20-15:40 | Japan’s progress and challenges with achieving the global targets to eliminate cervical cancer | **Kayo Togawa,** National Cancer Center **(virtual)**

15:40-16:00 | Proposed, Choi Kui Son

16:00-16:20 | Discussion

16:20 | Adjourn for the Day

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

###### Friday| 8 March 2024 | DAY FOUR

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

SESSION THREE: Hepatitis Virus-related and Non-viral Liver Cancer - Joint with Immunology Board and Cancer Panel 

*Moderators: Su-Hyung Park & Toru Kiyono*

8:30-8:45 | Sera of Individuals Chronically Infected with Hepatitis B Virus (HBV) Contain Diverse RNA Types Produced by HBV Replication and Derived from Integrated HBV DNA | Severin Gudima, USA

8:45-9:00 | Tatsuhiro Shibata, Japan

9:00-9:15 |  Regulatory Mechanism of Polycomb Repressive Complex 1 by HCV Infection | Kohji Moriishi, Japan

9:15-9:30 | ILT2 as a Regulator of NK Cells in Patients with HCC | Tatsuya Kanto, Japan

9:30-9:45 | Molecular Landscape of Liver Cancer and Its Clinical Implications | Xin Wei Wang, USA

9:45-10:10 | Discussion for Talks 20-24 

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

10:10-10:50 | Coffee Break

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*Moderator: Tatsuya Kanto* 

10:50-11:05 | 4-1BB Co-Stimulation, a Promising Strategy for Treating HCC | Su-Hyung Park, Korea

11:05-11:20 | mRNA-based T-cell Engineering for HBV-related HCC | Antonio Bertoletti, Singapore

11:20-11:35 | Ray Chung, USA

11:35-11:50 | Oxidative Stress Sensor Keap1 Recognixes HBx Protein to Activate the Nrf2/ARE Signaling Pathway, thereby Inhibiting Hepatitis B Virus Replication | Ikuo Shoji, Japan

11:50-12:05 | Epidemiology and Genomic Applications Detect Risk Factors and Discern Treatment Response in Liver Cancer | Anuradha Budhu, USA 

12:05-12:30 | Discussion for Talks 25-29

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

12:30-13:30 | Lunch Break

12:30-13:30 | Hepatitis Panel Business Meeting 

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*Moderators: Tatsuhiro Shubata & Xin Wei Wang* 

13:30-13:40 | Young Investigator 7 | Immune Resilience to Cancer by Repurposing Mycobacterium Tuberculosis-specific CD4 Memory Th1 Cells | Burcu Temizoz

13:40-13:50 | Young Investigator 8 | Single Nanoparticle Mapping and Sorting in Biological Fluids and Breath Samples | Shuntaro Shimizu

13:50-14:00 | Young Investigator 9 | A Novel Mechanism of Driving Intrahepatic Cholangiocarcinoma | Takahiro Kodama, Japan

14:00-14:10 | Young Investigator 10 | Differential T-cell and Monocyte Responses in Hepatocellular Carcinoma Treated with Regorafenib Plus Nivolumab | Hyung-Don Kum, Korea

14:10-14:20 | Young Investigator 11 | Laminin y2 Monomer, a Novel Biomarker for Hepatocellular Carcinoma in Patients with Chronic Hepatitis Virus Infection | Kouki Nio, Japan

14:20-14:30- Young Investigator 12 | Role of Hepcidin Upregulation and Proteolytic Cleavage of Ferroportin 1 in Hepatitis C Virus-induced Iron Accumulation | Kazuyoshi Ohta, Japan

14:30-15:00 | Discussion for Young Investigators 7-12

15:00-15:15 | Wrap-up and Plans for a Report | Ray Chung & Tatsuya Kanto

15:15| Adjourn 37th Hepatitis / Immunology / Cancer Panel Meeting 

---

## If you have any questions or technical issues please contact Annie King, [aking@crdfglobal.org](mailto:aking@crdfglobal.org)

![](https://www.crdfglobal.org/wp-content/uploads/2021/12/crdf-logo-white.svg)

#### Advancing U.S. national security by mitigating threats and enhancing opportunities through technology, innovation, and collaboration.

### Let us know how we can help you reach your goals

[Facebook Facebook](https://www.facebook.com/CRDFGlobal) [Twitter](https://twitter.com/CRDFGlobal) [Instagram Instagram](https://www.instagram.com/crdfglobal/) [Linkedin Linkedin](https://www.linkedin.com/company/crdf-global)[Contact Us](https://insights.crdfglobal.org/contact-us?hsLang=en)

- WHO WE ARE 
    - [Our Story](https://crdfglobal.org/our-story/)
    - [Mission, Vision & Values](https://crdfglobal.org/mission-vision-values/)
    - [Leadership](https://insights.crdfglobal.org/leadership?hsLang=en)
    - [Our Experts](https://insights.crdfglobal.org/experts?hsLang=en)
    - [Partners](https://insights.crdfglobal.org/partners?hsLang=en)
- WHAT WE DO 
    - [Chemical, Biological & Nuclear Security](https://www.crdfglobal.org/what-we-do/cbrne-security-counterproliferation/)
    - [Cybersecurity & Digital Resilience](https://www.crdfglobal.org/what-we-do/cybersecurity/)
    - [Research, Data & Emerging Technology Security](https://www.crdfglobal.org/what-we-do/research-data-and-technology-security/)
    - [Security Cooperation & Exchanges](https://www.crdfglobal.org/what-we-do/international-exchanges/)
    - [Border Security & Strategic Trade Controls](https://www.crdfglobal.org/what-we-do/strategic-trade-border-security/)
    - [Health Security & Research](https://www.crdfglobal.org/what-we-do/global-health/)
- HOW WE DELIVER 
    - [Travel & Logistics](https://www.crdfglobal.org/capabilities/travel-logistics/)
    - [Security Strengthening](https://www.crdfglobal.org/capabilities/security-strengthening/)
    - [Fellowships & Exchanges](https://www.crdfglobal.org/capabilities/fellowships-and-exchanges/)
    - [Grants & Research Competitions](https://www.crdfglobal.org/capabilities/grants-research-competitions/)
    - [Technical & Professional Training](https://www.crdfglobal.org/capabilities/technical-and-professional-trainings/)
    - [Specialized Equipment Procurement](https://www.crdfglobal.org/capabilities/specialized-equipment-procurement/)
    - [Program Design and Management](https://www.crdfglobal.org/integrated-solutions/program-design-and-management/)
    - [Monitoring, Evaluation and Learning](https://www.crdfglobal.org/integrated-solutions/monitoring-evaluation-and-learning/)
    - [Remote Training & Learning](https://www.crdfglobal.org/integrated-solutions/remote-training-and-learning/)
    - [Quality Framework](https://www.crdfglobal.org/integrated-solutions/quality-framework/)
- COLLABORATE 
    - [Become a Partner](https://www.crdfglobal.org/become-a-partner/)
    - [Grants & Procurement](https://www.crdfglobal.org/grants-procurement/)
    - [Procurement & RFPs](https://insights.crdfglobal.org/rfp?hsLang=en)
    - [Funding & Grants](https://insights.crdfglobal.org/funding-opportunities?hsLang=en)
- [WHERE WE WORK](https://crdfglobal.org/where-we-work/) 
    - [NEWS & INSIGHTS](https://www.crdfglobal.org/news/)
    - [CAREERS](https://www.crdfglobal.org/careers/)

[Privacy Policy](https://www.crdfglobal.org/data-privacy-policy/)    [Code of Conduct](https://www.crdfglobal.org/participant-code-of-conduct/)

© 2026 CRDF Global - All rights reserved